{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+Wet+Age-related+Macular+Degeneration+%28AMD%29", "query": { "condition": "Neovascular Wet Age-related Macular Degeneration (AMD)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 110, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+Wet+Age-related+Macular+Degeneration+%28AMD%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T21:51:49.020Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04514653", "title": "RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "Ranibizumab", "type": "BIOLOGICAL" }, { "name": "ABBV-RGX-314 Dose 1", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 2", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 3", "type": "GENETIC" }, { "name": "Local Steroid", "type": "DRUG" }, { "name": "Topical Steroid", "type": "DRUG" }, { "name": "ABBV-RGX-314 Dose 4", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 146, "start_date": "2020-08-25", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514653" }, { "nct_id": "NCT00464347", "title": "TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Avastin", "type": "DRUG" }, { "name": "Photodynamic Therapy (PDT)", "type": "PROCEDURE" }, { "name": "Preservative-Free Triamcinolone Acetonide (TAC-PF)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 100, "start_date": "2007-01", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2010-03-24", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 11, "location_summary": "Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00464347" }, { "nct_id": "NCT00893724", "title": "Supplemental Adjuvants for Intracellular Nutrition and Treatment", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neovascular Age-related Macular Degeneration", "Diabetic Macular Edema" ], "interventions": [ { "name": "Neutral pills with no medicinal effect", "type": "DRUG" }, { "name": "Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals", "type": "DIETARY_SUPPLEMENT" }, { "name": "Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Mid-Atlantic Retina Consultations, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 60, "start_date": "2009-06", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2011-07-20", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00893724" }, { "nct_id": "NCT05984927", "title": "NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "NG101 AAV gene therapy", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Elisigen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 20, "start_date": "2023-09-08", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05984927" }, { "nct_id": "NCT00509795", "title": "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "ranibizumab", "type": "BIOLOGICAL" }, { "name": "aflibercept injection (VEGF Trap-Eye, BAY86-5321)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1217, "start_date": "2007-08", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-12-28", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 176, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509795" }, { "nct_id": "NCT04757636", "title": "OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "2.0 mg OPT-302", "type": "BIOLOGICAL" }, { "name": "2.0 aflibercept", "type": "BIOLOGICAL" }, { "name": "Sham", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Opthea Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 998, "start_date": "2021-03-12", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 60, "location_summary": "Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04757636" }, { "nct_id": "NCT05986864", "title": "Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "SKG0106", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Skyline Therapeutics (US) Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 68, "start_date": "2024-02-23", "completion_date": "2027-01-30", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 4, "location_summary": "St. Petersburg, Florida • Boston, Massachusetts • Katy, Texas + 1 more", "locations": [ { "city": "St. Petersburg", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Katy", "state": "Texas" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05986864" }, { "nct_id": "NCT03699618", "title": "Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Submacular Hemorrhage", "Wet Macular Degeneration", "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Anti-VEGF", "type": "DRUG" }, { "name": "Hemorrhage displacement + Anti-VEGF", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1, "start_date": "2019-05-29", "completion_date": "2020-01-06", "has_results": false, "last_update_posted_date": "2020-02-19", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03699618" }, { "nct_id": "NCT04480463", "title": "A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wet Age-related Macular Degeneration", "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "SCD411", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sam Chun Dang Pharm. Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 576, "start_date": "2020-08-13", "completion_date": "2022-09-08", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 12, "location_summary": "Campbell, California • Clearwater, Florida • Coral Springs, Florida + 9 more", "locations": [ { "city": "Campbell", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Stuart", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04480463" }, { "nct_id": "NCT00767949", "title": "Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neovascular Age Related Macular Degeneration" ], "interventions": [ { "name": "iSONEP", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lpath, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 15, "start_date": "2008-10", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-04-16", "last_synced_at": "2026-10-08T21:51:49.020Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00767949" } ] }